Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Cinclus Pharma, Audiocast, Q1'25

By Inderes5/20/2025, 8:00 AM
Cinclus Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christer Ahlberg
00:00 - 16:45

Hello everyone, and welcome to Cinclus Pharma's first quarter 2025 earnings call. I'm Christer Ahlberg, CEO of Cinclus Pharma, and with me today is also our CFO, Maria Engström. We will present the latest developments from the first quarter of 2025 and the upcoming news flow, after which we will be happy to answer any questions you might have. Before we begin, though, I would like to share a quick reminder with our listeners that during today's call, management, Marie and I may make forward-looking statements that involve known and unknown risks, uncertainties, and other important factors beyond the company's control that could cause the company's actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. So please note that these forward-looking statements made during this call speak only as of today's date, and the company undertakes no obligation to update them to reflect subsequent events or circumstances, other than to the extent required by law. With those formalities out of the way. So let's begin with our lead asset. Discuss our lead asset Linaprazan glurate. It's actually a PCAB, as you know, a potassium competitive acid blocker. We have developed this primarily for the treatment of GERD, and Linaprazan represents a new class, the PCAB, which has the potential to replace the current standard treatment. The PPI, proton pump inhibitors. And we believe that our substance Linaprazan glurate really has the potential to become the best in class. And actually, it represents, I would say, the first application of that innovative mechanism of action. With 25 years of experience, our strategy focuses on the healing of severe patients, enabling us to aim for the specialty pharma commercial focus, which is important in this case. Additionally, it presents the greatest differentiation from the PPIs and the first generation of PCABs. And that gives us a strong competitive position in the future. And we have also seen that the positive Phase 2 results support our significant achievements, and we have de-risked the Linaprazan glurate program. And we are now progressing towards the Phase 3 study focusing on eGERD. As you know from before, we are backed by strong investors, including life science-focused institutional investors like Trill Impact Ventures, AP4, Linc AB, and Eir Ventures. And yes, some business updates. Then, as we have all discussed before, eGERD affects approximately 28 million adults in the US and Europe, including the 10 million with severe eGERD, which is our target population. Despite the availability of PPI therapy, we still see that approximately 10% of the mild patients, more than 30% of the moderate, and over 50% of the severe eGERD patients fail to achieve healing after eight weeks of treatment. In addition to that, we can also say that we see significant relapse from the current treatment, including perhaps the first generation of patients. So there definitely remains a significant unmet medical need and a substantial addressable market still. And we are currently progressing towards a Phase 3 study. As we have said, we have successfully finalized and completed the Phase 2 evaluation in Europe and also in the US, with close to 250 patients. The results were really, really good. We demonstrated a 93% healing rate among the most severe patients, which is our target population. Actually, we also observed a 100% healing rate in partial responders who had previously been treated with eight weeks of PPI treatment before the study. We are preparing to initiate the Phase 3 study now in Europe and the US. Returning to that, we will have the top-line results during 2026. Our current financial visibility suggests that we will have cash throughout the second quarter of 2026, covering the top line results. So, we will have the top-line results before we are running out of cash. In parallel to that, we are also working intensively on the business development activities that have been ongoing. Also for the first month here. Proceeding to the addressable market, we can observe more details here. The market in the US and EU demonstrates how substantial it is, with the potential market for Linaprazan glurate among people suffering from the most severe forms of eGERD estimated to be ten million in these regions and 90 million globally. So we can definitely see that we have blockbuster potential here. Just an overview of the global situation. What you can see is that PCABs are taking over the market from the old APIs and the standard treatment for gastric acid-related diseases in countries where they have been launched. Takeda and the Korean and Chinese manufacturers are increasing licensing, registering, and launching their products in the rest of the world markets, for instance, in Mexico. A PCAB has already secured the third position in the peptic ulcer market within its second year, and it has also achieved a notable price premium over PPIs, which is very interesting to follow. We can see that associations like physicians in India have recently issued broad consensus recommendations for the use of PCABs in managing acid peptic disorders, and at least 11 brands of PCABs have already been launched in the country, with more expected to come. Takeda is focusing on Linaprazan glurate production and strategic launches. On refocusing, I should say focusing on one product in Korea and Brazil, we see that there are more than 30 markets where we can see that PCABs are on sale and confirmed with the launches. We are really seeing activity around the PCAB heating up across the world. And just the latest example is the biggest gastric conference in the world, where we saw the most active PCB schedule ever, with more than 25 PCB-related presentations during those days we were there. So definitely, PCABs are on the topic now around the world. And we can clearly see here how Linaprazan glurate as a next-generation treatment can be compared both pharmacologically and clinically. Compared to the PPIs and the first generation of PCABs. I mean, such a person. We can see that Linaprazan glurate holds an advantage over the other treatment options with its. I mean, thanks to the program that we have developed, we see faster symptom relief. We observe the fastest healing and achieve the highest control percentages over a 24-hour period, which is essential for clinically healing the patients. And therefore, we also see very good healing results in half the time compared to the first generation, both to the PPI and the first generation of PCABs. We also have the ambition of showing superiority, both in achieving healing in half the time and in providing superior daytime and nighttime symptom relief, so we can achieve a best-in-class drug here. That is the ambition we have, and the substance definitely supports this potential. You have that potential. Another important factor in launching a product is the specificity, especially in the EU market, where we see a highly dynamic environment with multiple drugs. What possibilities? I think that is key in a market like this. This diagram shows how eGERD patients currently experience an acute healing phase followed by maintenance treatment before reverting to acute healing treatment again. This means that there is substantial market potential, despite us not being first to market. As long as Linaprazan glurate achieves best-in-class status, which is definitely something we have the possibility to do. And as an example here, even though we are not the first, we would like to be the best. Here's an example of the dynamics at play here. You can see in one episode from the first generation, perhaps 25% of patients relapsed within six months on maintenance treatment with that substance. And of course, that will increase over the 12-month period. So definitely, there are different switch possibilities to consider here. That's the reason why I also think this slide is interesting to look at, because our ambition at Cinclus is to develop a unique next-generation PCAB that meets the medical need and provides the conditions to do exactly what AstraZeneca did when they launched the next generation PPI, Nexium. In fact, 12 years after the introduction of Losec, or Prilosec, or Omeprazole. In other words, we would like to capture the market following the first generation. And as you can see, the sales figures show what AstraZeneca managed to achieve. They achieved it in quite a fast period of time. A dynamic market in combination with the best-in-class position is the key to managing to do something like that. And that's the reason why we believe that this is definitely a possibility. Also important is the IP protection, as Cinclus Pharma has robust patent protection for Linaprazan glurate in the US market. For instance, we have several patents, including a so-called polymorphic patent that protects the specific crystal structure of the drug until 2042. In addition to this, we have filed several more patent applications in the US, and we have similar protection in place or pending in the EU and other markets around the world. In practice, these strong patents provide protection against potential generic competition even after data exclusivity is expected to have expired, regardless of how long it lasts. Let's now get a quick summary of the key events from the first quarter of 2025. Overall, we are continuing to strengthen our presence and visibility in academia and the medical profession by participating in a number of industry and scientific conferences. During the quarter, we participated in the Carnegie Healthcare Conference with Nordic Biotech and the JP Morgan Healthcare Conference. Additionally, during this period, we signed third-party supply contracts related to Phase 3 clinical studies, so we are good to go. Now for this third quarter post-period, we published an article featuring the data from the Phase 2 study, demonstrating a high healing rate in patients with severe forms of erosive disease. We have held a scientific advisory meeting with NICE regarding the price and reimbursement for Linaprazan glurate. We had a very positive meeting with NICE. There is the British Institute for Health and Care Excellence. We also participated in the Disease Week in San Diego, where we presented, as I mentioned at the DW, data demonstrating Linaprazan glurate's strong acid effect along with the positive results from the optimized tablet formulation developed for the Phase 3 trials and future Cinclus commercialization. As you already know, we have informed you about this earlier. And then we also participated in the 14th Expert Strategies in Endoscopy and Gastrointestinal Laparoscopic Disorders in Kansas City. All in all, we have had a busy and very productive start to 2025. If we're looking forward now and specifically considering the Phase 3 trial. Here we have some more details on our planned study starting up in the third quarter with the first patient being recruited. This is a European-US study where we have a significant number of sites in seven countries in Europe as well as in the US. We intend to show that our drug candidate is more effective than Proton Pump Inhibitors, according to several study measures, including superior healing and superior symptom control. A positive outcome would make Linaprazan glurate unique in the market. We plan to start, as I already mentioned, patient recruitment. Now, in the third quarter of 2025. And we anticipate topline results during next year. And let's turn to the financials and to Maria. Please go ahead.

Maria Engström
16:45 - 20:59

Yeah, thank you, Christer. You can go to the next slide and I will talk about some financial highlights during the first quarter. The cash at the end of the period was 524 million. The R&D expenses consisted, of course, of our Phase 3 preparations, including CMC activities, along with the finalization of some preclinical studies. During the quarter, expenses as a percentage of opex were 83%, which is above the average of the last eight quarters, which is 80%. We also saw a slight increase in the number of employees within the medical field. We can go to slide 17. And here we see the year-over-year financial results, and the operating expenses increased. To 11.2 million SEK. And that was actually an increase of 11.2 million. And that was, of course, due to the Phase 3 preparations. As I said, there are CMC activities in the finalization of some preclinical studies as well. The R&D expenses were slightly higher, and that is due to additional personnel compared to last year. And also activities related to the company now being listed. The EBIT decreased by 11.2 million. And that is, as I just mentioned, due to the high operating expenses. The financial net increased by 14.3 million. This was partly due to interest from cash in the bank of 3.4 million. The remaining part, 10.9 million, was due to unrealized currency gains on group internal liabilities. We have a small tax expense due to corporate and cantonal tax from our Swiss affiliate. The net profit increased by 3.2 million SEK, and that was due to the high financial net. However, remember that part of that was the unrealized currency gain. Other current assets increased by 25.9 million SEK according to the balance sheet, and that was due to prepayments to the CRO. As we are preparing for the Phase 3 study. All in all, in accordance with the contract, the cash was managed appropriately. As I mentioned earlier, cash increased by 471.4 million SEK. And that was, of course, due to the new share issue back in June last year. The non-current liabilities decreased by 6.5 million, and that was due to paying off the second tranche of the tax liability that we have had in Switzerland since the move of the IP from our Swiss affiliate. This tax liability will be paid off this year. Current liabilities decreased by 123.2 million SEK. That is due to the offsetting of the shareholder loan in connection with the IPO back in June. If we go to the next slide here, we can see the shareholders as of the end of March, and we still have our IPO corner investors and our founders with us. So then I will turn back to you, Christer.

Christer Ahlberg
20:59 - 21:22

Okay, thank you, Maria. That just leaves us with my perspective. Important dates in the diary here. Including our AGM on Thursday. What are the important events this week? And with that, I will continue to the Q&A session. So please go ahead.

Maria Engström
21:25 - 21:44

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Arvid Nee Kinder from Carnegie. Please go ahead.

Christer Ahlberg
21:48 - 22:35

Good morning, and thanks for taking my questions. So first off, can you tell us anything about the reimbursement discussions you've had in Europe and whether or not they point to any meaningful differences in price or market access compared to what you've estimated in the past? And secondly, on the reference pricing model proposed by the Trump administration, I understand that there's a lot of uncertainty here, of course, but given the high price differential between the US and Japan, does this lead you to be a bit more cautious about pursuing partnerships outside the US? Given the risk of eroding the US potential? Yeah, those were my questions.

Maria Engström
22:35 - 24:09

Okay. Thank you for this question. The first question, as I mentioned, we had a meeting with NICE, and it was a very good meeting. It's quite obvious that the European authorities are looking forward to perhaps having her on board here in Europe as well as in the UK. It's quite clear what threshold we need to overcome, and that we're talking about cost-effectiveness and cost-efficiency. As long as we are cost-effective compared to the standard of treatment and we have a clear target population, definitely we can have a premium price. The willingness to pay for that is definitely there, and we are more confident about it after this meeting. So definitely, we see it as a good opportunity to get a premium price in the UK, where we had discussions, and that's what I can say about this being an advisory meeting. No, it's not a decision-making or anything like that. So, we are definitely confident that we can deliver a very cost-effective treatment in a specific target population. And therefore, we are maintaining that strategy, as you understand. Was that the question? Was that the answer to the first question?

Christer Ahlberg
24:12 - 24:19

Yeah. If you're able to elaborate on the threshold for being considered cost-effective, that would of course be interesting.

Maria Engström
24:19 - 27:51

Well, as you know, there are different discussions. You can discuss here whether a PPI definitely functions as intended. Even though we increase the doses, if you increase the number of doses per 24 hours, you have no possibility to increase the healing rates, actually more than on average what you can see. That was also mentioned by them. From them, more than 5%. So if you look into an overall review, that means that. Additionally, healing is definitely very important. You need to heal the patients. Otherwise, this disease can progress into much more severe conditions and result in cancer. So this is definitely something you can take into account when calculating cost efficiency. The other part is, of course, the symptoms, which are definitely evident when it comes to symptoms, as the quality of life is quite heavily impacted by these types of symptoms, including sleep disturbances, etc., and this will also have a major impact on cost efficiency for patients. And if you can, if you have superiority in this, then it's definitely possible to measure how. How you can achieve cost efficiency on that. If you combine both healing and symptom relief, you can achieve a very favorable price for this treatment. I will not delve into specific numbers, but we have previously provided guidance on price levels in Europe. And if you look into the maximum outcome of that, it is even higher, I would say. Going into the other question you had, of course, this is very speculative, and you can always discuss whether this can have an impact or not. What we have observed, though, is that this has been under discussion during many different presidencies, and we have not seen any differences yet. We are not that worried about it. But of course, we are following it very closely. I would say we do not expect that this will have an impact. Regarding other possibilities, it's about both US partnerships or the decision to handle pricing ourselves. We are also discussing the time factor here. I mean, our launch is estimated to be in four to five years, in 2029. So it's many years to go. The other part is also, of course, that we are still continuing our discussions. Overall, in other parts of the world, as well as with partnerships. So, we have not changed that strategy.

Christer Ahlberg
27:54 - 27:57

Great. That's very helpful. No further questions from me.

Maria Engström
28:05 - 28:22

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. To ask a question, please dial the pound key. Five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Christer Ahlberg
28:23 - 36:39

Well, there are some questions on the web here. And maybe I can touch on some of these regarding the funding, which I mentioned will be until the second part of 2026. With that said, we will also have a readout of the Phase 3 study during 2026. And our plan, according to our forecasting, indicates that we will have the readout before the end of the funding. So we will definitely have time to read it out and also raise more capital after that. I'm checking if we have more questions here. We also have questions about whether we are going to do head-to-head studies versus the first generation of PCABs. And that is, of course, a very interesting question. Of course, we are looking into these possibilities. However, as a regulatory clinical study, that is not what we want to do, nor is it typically what the regulatory authorities require us to do; we actually need to compare with the current standard of care. In Europe, for instance, we do not yet have NFP caps approved. So that's impossible to do that here and in the US. Definitely. It's very early. So definitely, it's not a standard of care there today. So that will not happen. But in the future, of course, that could be of interest to look into as a Phase 4 trial when we are on the market. Of course, we believe it's not necessary from a commercial point of view to have a head-to-head comparison with one person, for instance. Because if you just look at it, we know that we have significantly better acid control. And that is the perfect biomarker to estimate the healing rates. And what you can also see now, since we have that, is that we also notice the effect difference. I mean, a really, really big effect difference compared to the PPIs. We are using the same comparator as the other PCAB, which means that we can also have an indirect comparison of healing rates. Additionally, we know that none of the other PCABs have demonstrated superiority in terms of symptom relief. Thanks to our asset control, we definitely believe that this will be a possibility for us. And if we can do that, we have another differentiation factor, which is definitely also of importance here. We do have many different aspects that we can deliver. Showing that we are superior to the first generation PCABs. Either indirectly or directly. Without the need for a head-to-head comparison with another person, for instance. So we are confident that we can achieve that. This is also what we have historically observed. When you are changing from one product to another, you don't need to have a head-to-head comparison normally. Yes, and then we had some questions here regarding the IP issues with one entity. And if our drug is affected by the same thing? Well, no, we are not. I think that's important to mention. One person had their patent running out. 2013, and as a mitigation plan to have longer exclusivity. They actually plan to. One of the activities they initiated was to go for H. One of the activities they initiated was to go for H. Pylori indication as a first indication to extend the data exclusivity by five years by doing that. And that would have given them the exclusivity until 2032. But the FDA is now involved in a situation investigating the possibilities here, as the FDA has not accepted to grant the entire package, the entire substance, a five-year extension of exclusivity solely on the H. Pylori indication. And now, the dispute is regarding whether the data exclusivity extension should cover all indications. The data exclusivity extension should cover all indications here. If they win, we will know sometime this year, and they will have an extension of exclusivity until 2032. And that has been the problem for them, and for us. On the other hand, we do not have that problem since we have a very strong patent situation valid until 2042. An extension of our data exclusivity would simply be a bonus, allowing us to have combined control over both data exclusivity and patents. So for us, it doesn't matter. And then, of course, an additional question to that is whether it will have an impact on the pricing. And from our perspective, we have planned this since we will not be first in class. We have planned our drug to be superior and actually to launch this as a best in class treatment with superior acid control, which is needed for the severe patients. And that would be the case even though we are launching in a generic market or one that is close to becoming generic, similar to the situation we saw when Nexium was launched, which was also just before the lower segment of patent protection. As you can see from the diagram I showed you earlier, it didn't have any impact on the Nexium launch; I would say they had a really fast switch. Since there are many different switch opportunities in this dynamic market, we see that opportunity nevertheless. And that would have been the case in all instances here. And we have planned for that. Therefore, we are heavily focused on the specialty format target population, with superiority claims in both healing and symptom relief. So with that said, perhaps there are other questions arising based on these inquiries. So I give a last chance to provide us more questions. Okay. No more questions, then I stop there. And thank you for your interest and your time here. Let's stay in touch. Thank you. And have a nice day.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…